Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34)

This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of P...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-12, Vol.28 (2), p.415-421
Main Authors: Mongui, Alvaro, Angel, Diana I, Gallego, Gina, Reyes, Claudia, Martinez, Paola, Guhl, Felipe, Patarroyo, Manuel A
Format: Article
Language:English
Subjects:
Adult
Aged
Animals
Blotting, Western
Cytokines - metabolism
Electrophoresis, Polyacrylamide Gel
Fluorescent Antibody Technique, Indirect
Haplorhini - immunology
Haplorhini - metabolism
Haplorhini - parasitology
Humans
Malaria Vaccines - immunology
Middle Aged
Plasmodium vivax - immunology
Protozoan Proteins - immunology
Rabbits
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.10.034